Novel antidiabetic agent

Scientists from Scripps Research Institute and Harvard University’s Dana-Farber Cancer Institute have discovered a novel compound called SR1664, which they say could pave the way for a new class of diabetes medication, with fewer side effects than existing drugs. 

The study confirms previous research suggesting that blocking the action of enzyme Cdk5 on the protein PPARG is a viable target for antidiabetic agents. SR1664 is a potent binder to the nuclear receptor PPARG, but doesn’t activate gene transcription via the receptor’s normal mechanism.   

In the study, both the mice